In the context of tumor-specific T cell immune responses, CTLA-4 is understood to negatively regulate T cell priming events in secondary lymphoid tissues, leading to an unresponsive, anergic or apoptotic phenotype [57, 58]. This evidence concerns the gene CTLA4 and neoplasm.